Sector: Healthcare | Industry: Medical Equipment, Supplies & Distribution |
See Regulatory Filings on SEC |
Company Contact | |
Address: | 14445 Grasslands Drive ENGLEWOOD CO 80112 |
Tel: | N/A |
Website: | https://paragon28.com |
IR: | See website |
Key People | ||
Albert Dacosta Chairman of the Board, President, Chief Executive Officer | Stephen M. Deitsch Chief Financial Officer | Jason Allan Edie Chief Technology Officer |
Erik Mickelson Chief Accounting Officer, Controller | Jonathan I. Friedman General Counsel, Secretary | Matthew Jarboe Chief Commercial Officer |
Business Overview |
Paragon 28, Inc. is a medical device company. The Company develops, distributes, and sells medical devices in the foot and ankle segment of the orthopedic implant marketplace. Its products and product families include plates and plating systems, screws, staples, and nails to address all foot and ankle procedures, including fracture fixation, forefoot, or hallux valgus, which includes bunion and hammertoe, ankle, flatfoot, or progressive collapsing foot deformity (PCDF), Charcot foot and Ortho biologics. It provides a comprehensive portfolio of solutions that includes surgical implants and disposables, as well as surgical instrumentation. The Company's suite of surgical solutions comprises 75 product systems, including approximately 9,200 SKUs, which comprises of approximately 6,800 implants, 1,400 instruments and 1,000 disposable and other SKUs. Its products are available in a variety of sizes and configurations to suit the individual patient's anatomical and surgical requirements. |
Financial Overview |
For the fiscal year ended 31 December 2023, Paragon 28 Inc revenues increased 19% to $216.4M. Net loss decreased 29% to $47.8M. Revenues reflect United States segment increase of 16% to $183.5M, International segment increase of 41% to $32.9M. Lower net loss reflects Legal Settlement decrease from $27M (expense) to $0K, Other (expense) income - Balancing value increase from $2.5M (expense) to $945K (income). |
Employees: | 430 as of Dec 31, 2023 |
Reporting Currency: | U.S. Dollars |
Enterprise value: | $778.47M as of Dec 31, 2023 |
Annual revenue (TTM): | $216.39M as of Dec 31, 2023 |
EBITDA (TTM): | -$21.77M as of Dec 31, 2023 |
Net annual income (TTM): | -$47.84M as of Dec 31, 2023 |
Free cash flow (TTM): | -$91.92M as of Dec 31, 2023 |
Net Debt Last Fiscal Year: | $34.80M as of Dec 31, 2023 |
Shares outstanding: | 82,906,136 as of Mar 18, 2024 |
TTM: Trailing Twelve Months EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization |